However, it should also be noted that some other drugs, including epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, may activate the IL-31/IL-33 axis as their adverse effect and initiate dermatitis, presumably by damaging keratinocytes and causing the release of IL-33 [93]. This evidence concerns the gene IL33 and skin disorder.